Prostate

Article	Citations
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial	42
The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement	42
ATF6α promotes prostate cancer progression by enhancing PLA2G4A‐mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis	40
Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF‐1 upregulation of TUBB2B beta‐tubulin isoform	34
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment	31
177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis	28
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer	28
Clinical and genomic features of SPOP‐mutant prostate cancer	27
PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications	27
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment	23
SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)	23
225Ac‐PSMA‐617‐targeted alpha therapy for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis	23
Rezūm for retention—retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia	21
Real‐world evidence with The Rezūm System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes	20
Current and projected number of years of life lost due to prostate cancer: A global study	20
Barriers and facilitators of germline genetic evaluation for prostate cancer	20
Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities	19
Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores	18
Prostate cancer detection rate in men undergoing transperineal template‐guided saturation and targeted prostate biopsy	17
Prognostic role of pan‐immune‐inflammation value in patients with metastatic castration‐resistant prostate cancer treated with androgen receptor‐signaling inhibitors	16
PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence	16
Melatonin attenuates prostatic inflammation and pelvic pain via Sirt1‐dependent inhibition of the NLRP3 inflammasome in an EAP mouse model	16
Circular RNA circANKS1B acts as a sponge for miR‐152‐3p and promotes prostate cancer progression by upregulating TGF‐α expression	16
Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer	16
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients	15

Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy	15
Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis	15
Twenty‐year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort	15
Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer	15
Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial–mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway	15
Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based study	15
Prospective study of diagnostic accuracy in the detection of high‐grade prostate cancer in biopsy‐naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test	15
Plasma IL‐6 and TNF‐α levels correlate significantly with grading changes in localized prostate cancer	14
The effect of lymph node dissection on cancer‐specific survival in salvage radical prostatectomy patients	14
Influence of androgen deprivation therapy on the severity of COVID‐19 in prostate cancer patients	14
PSMA‐positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state	14
Mismatch repair deficiency and clinical implications in prostate cancer	14
Combined 177Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing t	14
Prostate‐to‐bladder cross‐sensitization in a model of zymosan‐induced chronic pelvic pain syndrome in rats	13
Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy	13
Knowledge of prostate cancer among African American men: A systematic review	13
Stromal cell interplay in prostate development, physiology, and pathological conditions	13
Characterization of tumor‐associated macrophages in prostate cancer transgenic mouse models	13
Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone‐sensitive prostate cancer	13
Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer	13
Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy	13
Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo	12
Protein signatures to distinguish aggressive from indolent prostate cancer	12
Evaluating post radical prostatectomy mechanisms of early continence	12
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index	12
Early‐onset prostate cancer is associated with increased risks of disease progression and cancer‐specific mortality	12
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer	12
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations	12
Identification of the metabolic signatures of prostate cancer by mass spectrometry‐based plasma and urine metabolomics analysis	12
M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulin‐like growth factor 1 knockdown	12
Gonadotropin‐releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin‐releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study	11
SIRT3 affects mitochondrial metabolic reprogramming via the AMPK–PGC‐1α axis in the development of benign prostatic hyperplasia	11
Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer	11
Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association	11
Single‐port versus multiport robotic‐assisted radical prostatectomy: A systematic review and meta‐analysis on the da Vinci SP platform	11
Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long‐term follow‐up study	11
Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer	11
Comparison of 68Ga‐PSMA PET/CT and mp‐MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study	11
Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients	11
MRI‐detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern	11
Observed evidence for guideline‐recommended genes in predicting prostate cancer risk from a large population‐based cohort	11
Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer	11
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD‐L1 expression by C5a	11
Bipolar androgen therapy (BAT): A patient's guide	10
Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis	10
The evolving landscape of prostate cancer somatic mutations	10
Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level	10
Role of Runx2 in prostate development and stem cell function	9
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer	9
PSMA‐heterogeneity in metastatic castration‐resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy	9

Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?	9
The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers	9
Spatial and temporal patterns of prostate cancer burden and their association with Socio‐Demographic Index in Asia, 1990–2019	9
DNA‐PKc inhibition overcomes taxane resistance by promoting taxane‐induced DNA damage in prostate cancer cells	9
Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy	9
Phenotypic characterization of two novel cell line models of castration‐resistant prostate cancer	9
Germline genetics of prostate cancer	9
CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer	9
Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno‐geographic variations	9
Single‐cell atlas of epithelial and stromal cell heterogeneity by lobe and strain in the mouse prostate	9
Therapeutic effects of nerve growth factor‐targeting therapy on bladder overactivity in rats with prostatic inflammation	9
Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation	9
Pilot study of the diagnostic utility of 89Zr‐df‐IAB2M and 68Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer	9
Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins	9
Prostate tumors of native men from West Africa show biologically distinct pathways—A comparative genomic study	9
Long‐term outcomes of Holmium laser enucleation of prostate and predictive model for symptom recurrence	8
A systematic review and meta‐analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome	8
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer	8
SPOP andCHD1alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence	8
Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients	8
The role of transurethral resection of prostate (TURP) in patients with underactive bladder: 12 months follow‐up in different grades of detrusor contractility	8
Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer	8
Rates and trends in stage‐specific prostate cancer incidence by age and race/ethnicity, 2000–2017	8
Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn‐ or metachronous metastatic disease	8
Paracrine Wnt signaling is necessary for prostate epithelial proliferation	8
STAT3 phosphorylation is required for the HepaCAM‐mediated inhibition of castration‐resistant prostate cancer cell viability and metastasis	8
Artificial intelligence trained with integration of multiparametric MR‐US imaging data and fusion biopsy trajectory‐proven pathology data for 3D prediction of prostate cancer: A proof‐of‐concept study	8
Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5‐alpha reductase inhibitor treated human benign prostate hyperplasia patients	8
Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides	8
Long‐term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life‐table data	8
Machine learning algorithms can more efficiently predict biochemical recurrence after robot‐assisted radical prostatectomy	8
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer	8
Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy	8
Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling	8
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer	8
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients	7
Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms	7
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms	7
Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga‐PSMA‐PET/CT in prostate cancer patients candidate to definitive radiotherapy	7
Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer	7
Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidates	7
Prevalence of prostate cancer at autopsy in Nigeria—A preliminary report	7
Combination with vorinostat enhances the antitumor activity of cisplatin in castration‐resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH	7
The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot‐assisted laparoscopic radical prostatectomy	7
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel‐resistant prostate cancer	7
Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings	7
Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy	7
Postoperative peripheral neuropathies associated with patient positioning during robot‐assisted laparoscopic radical prostatectomy (RARP): A systematic review of the literature	7
Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: Performance of a fully automated AI‐algorithm for lesion detection and classification	7
Impact of therapy on cancer metabolism in high‐risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy	7
A new flavonoid derivative exerts antitumor effects against androgen‐sensitive to cabazitaxel‐resistant prostate cancer cells	7
The influence of low‐carbohydrate diets on the metabolic response to androgen‐deprivation therapy in prostate cancer	7
Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants	7
An update on the current status and future prospects of erectile dysfunction following radical prostatectomy	7
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA‐related parameters to enhance the detection of clinically significant cancer across different region	7
Comparison between 18F‐DCFPyL PET and MRI for the detection of transition zone prostate cancer	7
Risk of major adverse cardiovascular events among second‐line hormonal therapy for metastatic castration‐resistant prostate cancer: A real‐world evidence study	7
Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer	7
Comparing two different low‐intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two‐arm, parallel‐group randomized controlled trial	6
Application of European‐specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations	6
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases	6
Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy	6
The effect of primary urological cancers on survival in men with secondary prostate cancer	6
Association of germline rare pathogenic mutations in guideline‐recommended genes with prostate cancer progression: A meta‐analysis	6
Clinical, pathologic, and molecular features of amphicrine prostate cancer	6
TMPRSS2‐ERG fusion impacts anterior tumor location in men with prostate cancer	6
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer	6
Transcript analysis of commercial prostate cancer risk stratification panels in hard‐to‐predict grade group 2–4 prostate cancers	6
Genomic characterization of metastatic castration‐resistant prostate cancer patients undergoing PSMA radioligand therapy: A single‐center experience	6
Contemporary seminal vesicle invasion rates in NCCN high‐risk prostate cancer patients	6
MEX3D is an oncogenic driver in prostate cancer	6
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer	6
TALEN‐mediated generation of Nkx3.1 knockout rat model	6
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA‐targeted radioligand therapy	6
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series	6
Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities	6
Cardiovascular outcomes among patients with castration‐resistant prostate cancer: A comparative safety study using US administrative claims data	6
Prostate cancer awareness among transgender women after gender‐affirming surgery	6
Expression and prognostic significance of vascular endothelial growth factor‐A (VEGF‐A) and its receptor in canine prostate cancer	6
Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism‐related genes act as prognostic signatures for prostate cancer	6

Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells	6
Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7	6
AT‐rich interaction domain 5A regulates the transcription of interleukin‐6 gene in prostate cancer cells	6
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality	6
SOX9 and HMGB3 co‐operatively transactivate NANOG and promote prostate cancer progression	6
Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805	5
Identification of novel susceptibility factors related to CP/CPPS‐like symptoms: Evidence from a multicenter case‐control study	5
4‐Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy for chronic prostatitis	5
Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patients	5
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients	5
Diagnostic performance of microUltrasound at MRI‐guided confirmatory biopsy in patients under active surveillance for low‐risk prostate cancer	5
Lymphocyte‐to‐monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy	5
Stratification of prostate cancer patients into low‐ and high‐grade groups using multiparametric magnetic resonance radiomics with dynamic contrast‐enhanced image joint histograms	5
Sociodemographic index and global trends in prostate cancer: 1990–2017	5
Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software‐based systems	5
Development of a novel castration‐resistant orthotopic prostate cancer model in New Zealand White rabbit	5
Metagenomics studies for the diagnosis and treatment of prostate cancer	5
Continuity of care in acute survivorship phase, and short and long‐term outcomes in prostate cancer patients	5
Surgical and functional outcomes of Retzius‐sparing robotic‐assisted radical prostatectomy versus conventional robotic‐assisted radical prostatectomy in patients with biopsy‐confirmed prostate cancer.	5
Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration‐resistant prostate cancer	5
The use of 68Ga‐PSMA PET/CT to stratify patients with PI‐RADS 3 lesions according to clinically significant prostate cancer risk	5
Impact of mpMRI targeted biopsy on intraoperative nerve‐sparing (NeuroSAFE) during robot‐assisted laparoscopic radical prostatectomy	5
Combination therapy with novel androgen receptor antagonists and statin for castration‐resistant prostate cancer	5
Lack of repeatability of radiomic features derived from PET scans: Results from a 18F‐DCFPyL test–retest cohort	5
Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro‐oncology registry	5
Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983	5
Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy	5
An Australian experience using Tc‐PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy	5
Diagnosis and management of neuroendocrine prostate cancer	5
Smoothened loss is a characteristic of neuroendocrine prostate cancer	5
Identification of androgen response‐related lncRNAs in prostate cancer	5
βArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration‐resistant prostate cancer	5
Optimization of prostate cancer patient lymph node staging via the integration of neutrophil–lymphocyte ratios, platelet–lymphocyte ratios, and 68Ga‐PSMA‐PET‐derived SUVmax values	5
What are survivorship care plans failing to tell men after prostate cancer treatment?	5
The characteristics and spatial distributions of prostate cancer in autopsy specimens	5
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+	5
Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p‐STAT3 in prostate cancer	5
SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer	5
Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience	5
Evidence for a causal effect of major depressive disorder, anxiety on prostatitis risk: A univariate and multivariate Mendelian randomization study	5
Functional outcome after radical prostatectomy in 1313 patients: A single‐center study	5
Safety of concomitant therapy with radium‐223 and abiraterone or enzalutamide in a real‐world population	5
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients	5
Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics	5
Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literature	5
High‐intensity interval training attenuates the effects caused by arterial hypertension in the ventral prostate	5
Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6‐mediated Axl and RON signaling	5
CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation	5
Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross‐sectional study	5
A matter of size? Health‐related quality of life after radical prostatectomy for patients with giant prostates	5
Racial differences in circulating mitochondria‐derived peptides may contribute to prostate cancer health disparities	5
Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study	5
Ultrasound‐based radiomics score for pre‐biopsy prediction of prostate cancer to reduce unnecessary biopsies	4
PSA provocation by bipolar androgen therapy may predict duration of response to first‐line androgen deprivation: Updated results from the BATMAN study	4
Seleno‐aspirin compound AS‐10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells	4
Clinical significance of unfavorable findings in intermediate‐risk prostate cancer patients for predicting treatment outcomes after contemporary, dose‐escalated multimodal radiotherapy	4
Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study	4
Immune mechanisms behind prostate cancer in men of African ancestry: A review	4
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer	4
A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide	4
Microultrasound in the detection of the index lesion in prostate cancer	4
The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis‐free survival in patients with relapsed prostate cancer following prostatectomy	4
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy	4
Factors impacting on sexual function among men on active surveillance for prostate cancer	4
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups	4
Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy	4
Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma	4
Prostate and testicular growth analysis in human fetuses during the second gestational trimester	4
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy	4
Future directions for precision oncology in prostate cancer	4
Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: A randomized clinical trial	4
Optimized grade group for reporting prostate cancer grade in systematic and MRI‐targeted biopsies	4
Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy	4
Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis	4
4‐Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome‐induced pyroptosis through activating Nrf2/HO‐1 pathway	4
Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration‐resistant prostate cancer	4
Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation	4
Prostate cancer grade downgrading at time of prostatectomy provides risk‐stratification insight into future tumor behavior after prostatectomy	4
Molecular features and race‐associated outcomes of SPOP‐mutant metastatic castration‐resistant prostate cancer	4
Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study	4
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer	4
Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis	4
Targeting glutamine dependence with DRP‐104 inhibits proliferation and tumor growth of castration‐resistant prostate cancer	4
Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL‐17 signaling pathway gene LCN2 in castration‐resistant prostate cancer	4
O‐glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer	4
Quality of life after robotic‐assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP‐01)	4
Prostate magnetic resonance imaging‐targeted biopsy global grade correlates better than highest grade with prostatectomy grade	4
Prospective role of 3βHSD1 in prostate cancer precision medicine	4
CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma	4
The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging	4
DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries	4
Inverse agonism at the Na/K‐ATPase receptor reverses EMT in prostate cancer cells	4
Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan‐confined prostate cancer	4
CTPC, a combined transcriptome data set of human prostate cancer cell lines	4
Importance of magnetic resonance imaging and prostate‐specific membrane antigen PET‐CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer	4